Top Banner
Moise Danielpour, M.D. Vera and Paul Guerin Family Chair in Pediatric Neurosurgery Medical Director, Pediatric Neurosurgery and Center for Pediatric Neurosciences Department of Neurosurgery and The Regenerative Medicine Institute Cedars-Sinai Medical Center
77

Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

Mar 29, 2018

Download

Documents

doliem
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

MoiseDanielpour,M.D.VeraandPaulGuerinFamilyChairinPediatricNeurosurgeryMedicalDirector,PediatricNeurosurgeryandCenterforPediatricNeurosciencesDepartmentofNeurosurgeryandTheRegenerativeMedicineInstituteCedars-SinaiMedicalCenter

Page 2: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  ConsultantforBiomarinPharmaceuticalsforclinicaldrugtrialforforamenmagnumstenosisinachondroplasia

¡  Noconflictofinterest

Page 3: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

0 500 1000 1500 2000

CancerRemainsaLeadingCausesofDeathamong1-14Year-OldsU.S.,1991vs.1998

AccidentsCancer*

BirthDefectsHomicide

HeartDiseasesPneu&Influenza

CerebralPalsySuicide

HIVInfectionObstruc.LungDis.

Dis.ofInfancyCerebrovasc.Dis.

SepticemiaViralDiseases

Meningitis

19911998

1991:Ca-ACaJforClinJan-Feb,'951998:Ca-ACaJforClin51:15-36,'01

*includesfatal'benign'tumors

51896325

Page 4: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡ Morethan7000newcasesofchildhoodcancersarediagnosedeachyearintheUnitedStates

¡  CentralNervousSystem(CNS)Tumorsarethemostcommonsolidtumorofchildhood

¡  ThemorbiditycausedbyCNStumorsandtheirtreatmentexceedsthatofmostotherchildhoodcancers

Page 5: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  EarlydiagnosisandextentofsurgicalresectionofCNStumorsinchildrenarethestrongestpredictorsofincreasedsurvivalorcure§  SignsandSymptoms§  RoleofSurgeryandChemotherapy▪  AdvancesleadingtodecreasedMorbidity

§  PrecisionMedicineandPersonalizedModelingofCancers

§  Advancesinthelaboratory

Page 6: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Seizures¡  Ataxia/Dysmetria¡  Vomiting¡  CranialNeuropaties¡  Macrocephaly

§  Nausea§  Headache§  VisualDisturbance§  AlteredMentalStatus§  Pain§  Weakness

Page 7: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Occursin84%ofpediatricpatientswithbraintumors

¡ MaybeduetogeneralizedelevatedICP,orcompressionofvagalnucleiorvomitingcentersinflooroffourthventricle

¡  Earlymorningheadachesandvomiting¡ Waxingandwaningsymptomsoftenwithimprovementofheadachesafteremesis

Page 8: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Rareearlyindicationofamasslesion:§  Initialpresentationin15%ofchildrenwithsupratentoriallesions

¡  Temporallobemostcommonsitefortumorsproducingseizuresasanearlysign§  Canpresentasabsenceseizures§  Difficulttodetect:staring,Lackofawareness,suddenhaltinactivity,lipsmackingetc.

§  behavioralissuesanddeclineinschoolperformance

Page 9: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Gaitdisturbancesmaysuggesteitherabrainstemorcerebellarprocess

¡  Triadoflong-tractsigns,cranialneuropaties,andataxiasuggestsbrainstempathology

¡  Cerebellarlesions§  Midlinelesions=truncalataxia

§  Cerebellarhemisphere=Appendicularataxia

Page 10: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Seeninmultipletypesofbraintumors¡  Producedbydirectcompression/invasionor¡  IndirectlyduetoincreasedICP

§ MostcommonlyCNVI▪  Diplopiawithcomplimentarystrabismusorheadtilt

Page 11: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  MostCommon--Diplopia,asymmetriccranialnervedeficitsanddifficultywalking

¡  HydrocephalusSyndrome--Headaches,vomitingandventriculomegaly

¡  PsychiatricSyndrome1--Apathy,depression,declineinschoolperformanceandmemoryloss

¡  PsychiatricSyndrome2--Behavioralchange,nightmaresandenuresis

¡  StrokeorhemorrhagicSyndrome--Acutestrokelikeonsetofhemiplegia,quadraparesis,intra-nuclearophthalmoplegiaandupbeatnystagmus

¡  --Cerebello-pontineanglepresentationwithinvolvementofcranialnervesV,VIIandataxia

Page 12: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Backpaininachildmaybewarningofundelyingspinalcordlesion§ Whenpresentingwithintracranialsignsorsymptomsmayrepresentadropmetastasisfromintracranialtumor

Tumorwithdropmetastasis

Page 13: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡ Weaknessofextremetiescommonlyseenwithsupratentorialtumors

¡  Canbepresentingsignofspinalcordcompression

¡  Otherassociatedsignsandsymptomsmustbeelicitedtodifferentiatebetweenthetwotypesofpresentation

Page 14: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 15: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  YoungchildrencanaccommodatelargetumorswithminimalsignsofraisedICP

¡  PresenceofopensuturesorfrontalbossingisalongstandingsignofincreasedICP.

¡  Imperativetomeasureachild’sheadcircumferenceifanysignsofachangeinmentalstatus,irritabilityorlethargyoccurs.

Page 16: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Directinvolvementofvisualpathway§  Opticglioma,hypothalamicgliomas,visualcortexandcraniopharyngioma:visualfieldcuts

§  pinealandtectalplatetumors:perinaud’ssign¡  Papilledemasecondarytoraisedintracranialpressure§  Presentinupto90%ofpatientswithcerebellarastrocytoma

Page 17: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Growthdisturbances¡  Precociouspuberty¡  Amenorrhea¡  Hypothyroidism¡  Diabetesinsipidus

Page 18: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  42%ofpatientspresentwithhormonaldeficiency(D.I.)andprecociousordelayedpuberty

¡  Ophthalmologicexaminationiscriticalbecausepatientsrarelycomplainofvisualdisturbance

¡  Visualcutsarecommonlyfoundonexam

Page 19: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 20: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Frequentlypresentwithhormonaldeficiency¡  Over50%presentwithgrowthhormonedeficiency

¡  Over91%ofpatientshavehypopituitarismwithmultiplehormonaldeficiencies

¡  DiabetesInsipidusisalatesignandfrequentlyunderappreciated

Post-op

Pre-op

Page 21: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Parinaud’ssign§  Paralysisofupwardgazewithretractionnystagmus,pupillarylight-near

dissociation,lidretraction¡  Raisedintracranialpressure:hydrocephalus¡  Diplopia¡  Diabetesinsipidus¡  Hypopituitarism

Pre-opPost-op

Page 22: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 23: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

0102030405060708090100

resection>90% Residual<1.5cc neurologicalcomplications

GNSDPNSASPN

Page 24: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 25: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

SurgicalResection

Page 26: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

Page 27: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

Neuroanatomy Microneurosurgery Imaging

Page 28: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

PRE-OPERATIVEIMAGE

POST-OPERATIVEIMAGE

BRAINTUMOR

Page 29: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 30: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 31: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 32: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Realtimeimages¡  Canaccountforbrainshift¡  Ideallysuitedforuseinchildren

§  Smallersurgicalfield

§  Higherincidenceoflow-gradetumors

§  Donotneedtousetraditionalheadholdingapparatus

Page 33: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  AFlexibleLaserapplicatorisguidedtointendedtargetedarea

¡  IntheMRIunitaphysicalpreciselymonitorstreatmentusingsoftwaretomeasuretemperaturechange

¡  Laserlightheatsanddestroystargetarea.Temperaturemapsshowextentoftumortissuebeingdestroyed,minimizingriskofdamagetosurroundinghealthytissue

Page 34: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  DeterminantsofDrugEfficacy§  Sensitivityoftumortothedrug

§  Pharmoracokineticsofthedrug

§  Drug’sabilitytocrosstheBBB§  Abilityoftumorcellstoaccumulateandretainthedrug

§  Abilityofthetumorcellstorepairdamagecausedbythedrug

Page 35: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  MalignantGlioma§  Increasesthediseasefreesurvivalinbothanaplasticastrocytoma(30%)andGlioblastoma(20%)whenusedfollowingradiotherapyascomparedtothosetreatedwithpostsurgicalradiotherapyalone.

¡  Medulloblastoma§  Upto80%fiveyeardiseasefreesurvivalfollowinggrosstotalresection,radiationandchemotherapycomparedtoabout40%withoutchemotherapy

Page 36: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Ependymoma§  Chemotherapoyhasnotimprovedsurvival

¡  Oligodendrogliomas§  Verylittledataexistregardinguseofchemotherapyforchildrenwithnewlydiagnosedorrecurrentdisease

¡  GermCellTumors§  Dependsonthetypeofgermcelltumor

Page 37: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

Leptomeningealtumor

Chemotherapy

Drop-Mets?

Page 38: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

TUMORPAINTOptides;targetedtreatmentstokillcacercellswhilesparing

patientsfromtoxiceffectsofchemotherapy

-1993teamatHarvardidentifiedcomponentofscorpianvenomthatblockschloridechannels-1994NicoleUllrichandHaraldSontheimerusedCholorotoxintoblockmovementofGliomacellsandfoundcompoundonlybindsmalignantcells-TransmolecularPhase1andPhase2trials-JimOlsonandBlazeBiosciencewithtumorpainttovisualizetumorinsurgery-Makesurgeonsabletoremovemoretumorwithouthdisturbingnormaltissue-Attachchemotherapeuticdrugstoabindingagentthatonlyattachestotumorcells

Page 39: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Matchingtherightpatient,totherightmedicine,attherighttime.

¡  Mosttumorsdon’thaveasinglegenemutationorsingleabnormalpathway

¡  Mostbraintumorsareheterogenousandconstantlyevolving

Needtogainadeeperunderstandingofmolecularcharacteristicsthataredrivingtumorgrowthand

matchingtreatmenttothosespecificabnormalities

Page 40: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Pediatricgliomasareassociatedwithuniquemutations

¡  Pediatricgliomasoftenresemble“normal”developmentalprograms(e.g.EGLprogenitorsinmedulloblastoma)

¡  PediatricdiseasemorefrequentlypresentsaslowgradewhileadultpresentsasGBM

¡  Notablypediatricdiseasepresentsuniquechallengesduetocoincidentbraindevelopment

Page 41: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Next-gensequencinghasleadtorapiddeterminationofthesomaticmutationsinlowandhighgradegliomas

¡  PediatricGlioma§  Schwartzentruberetal.2012,

Nature§  Zhangetal.2013,NatureGenetics

¡  AdultGlioma§  Brennanetal.2013,Cell§  WilliamsParsonset.al.2008,

Science§  Frattiniet.al.2013,NatureGenetics§  TCGA2008,Nature§  Verhaaketal.2010,CancerCell

Page 42: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Identifytarget¡  Findspecificdrugsorcombinationsofdrugsthatattackthosetargets

¡  Identifybiomarkersthatcanpredictwhichcombinationofdrugswillbeeffectiveforsubgroupofpatient(s)

Page 43: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Thereareanaverageof15somaticmutationsinpediatricglioma—relevanceofeachmutationnotclear

¡  Foradultthisnumberrisesto36somaticmutations

¡  Manymutationsdonothavegeneticallyengineeredmousemodels

Schwartzentrubereta.2012;Nature

Page 44: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  EngineeredMouseModels§  Costly§  Takemonths/yearstodesign§  Moretimetocross§  EvenwithatransgenicpromotersuchasNestin,a“non-

physiological”amountofcellsexpressthemutationthroughoutdevelopment

¡  ViralModels§  Safetyconcerns(pantropic)§  Needskillinachievinghightiters§  BreedingneededforRcas-Tvamodels(ecotropic)

¡  TransplantModels§  Immuneinteractionsanissue§  Notautochthonicandlikelydoesnotrecapitulatetumorigenic

process

Page 45: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

Developmentofanovelmethodologyforrapidandefficientgenerationofbraintumormodels

Page 46: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  ElectroporationistheapplicationofcurrentacrosstheheadtodriveplasmidDNAintothenucleiofdividingcells

¡  Postnatalelectroporationisasimple,“non-invasive”proceduretakinglessthan1hourperlittertocreatesomatictransgenics

Page 47: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 48: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 49: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 50: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Veryfewplasmidsstablyintegrate

Page 51: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Employs“pBase”transposasetostablyintegratethe“geneofinterest”intothegenomeinatargetedfashion

¡  AdaptedbyLoturcoetal.foruseintheembryonicCNS

Page 52: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Postnatalelectroporationallowsfortemporalandspatialcontrolofsomatictransgenesis

¡  PiggyBactranspositionprovidesforpermanenttransgeneintegration

Page 53: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

CRISPR/Cas9systemcanbeusedforgeneediting•  Genesilencing•  Replacingnormalgenewithmutantgene

https://www.neb.com/tools-and-resources/feature-articles/crispr-cas9-and-targeted-genome-editing-a-new-era-in-molecular-biology

Page 54: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Stable,somatictransgenicmutation¡  Labelandmutatesimultaneously(i.etumorcellsare

fluorescentagainstawildtype,unlabeledbackground)

¡  Flexible-Multiplegenes/shRNAscanbedeliveredsimultaneously(i.e.patientmutationsignatures)

¡  Autochthonic–fromendogenouscells,allowingnaturalprogressionoftumors

¡  Non-viral–nosafety/immuneconcerns¡  Rapid–requiresonlyPiggyBac-baseddonorplasmids¡  Definedinitialmagnitudeofsomatictransgenesisas

wellasthespatialandtemporalgenesisofthetumor

Page 55: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 56: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  TheMAPKpathwayishighlyimplicatedingliomagenesis

¡  Rasmutationsareseenin20-25%ofcancers

¡  Erbb2(HER2/Neu)formsaheterodimerwithotherErbb2familymembersandmutationsarefoundinglioma

http://www.biooncology.com/images/therapeutic-targets/

Page 57: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

RachelleLevyShawnWagner

Page 58: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

RachelleLevy

Page 59: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

RachelleLevy

Page 60: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Thecriticalpathologicalhallmarksarenoted

SergueiBannykh,M.D.

Page 61: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

RoelVerhaak,Ph.D.

Page 62: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 63: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

•  miR-Etechnologyisanevolutionofmir30microRNAtechnology•  CanbeusedwithPolIIpromoters(CAG,TRE-Bi,tissuespecificpromoters,etc.)•  Nf1functionstoinhibitRasactivationandisafrequentmutationinpediatricglioma

Page 64: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 65: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

Schwartzentruberetal.2012,Nature

Page 66: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 67: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 68: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 69: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 70: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 71: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 72: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  InhibitionofFattyAcidSynthaseDecreasesExpressionofStemnessMarkersinGliomaStemCells.Yasumotoetal.PloSOne2016Jan25;11(1)

¡  TERTpromotermutationsingliomas,geneticassociationsandclinico-pathologicalcorrelations.LabussièreM1etal,BrJCancer.2014Nov11;111(10):2024-32.doi:10.1038/bjc.2014.538.Epub2014Oct14.

Page 73: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Smallmolecules§  Fasn

¡  Geneticproofofprinciple§  Etsfamily

¡  Immunotherapy§  Tgr1-3

Page 74: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

ADDRESSINGTUMORRECURRANCE

74

Page 75: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 76: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer
Page 77: Consultant for Biomarin Pharmaceuticals for stenosis in …aapca2.org/wp-content/uploads/2016/04/Dr.-Danielpour-Pediatric... · ¡ No conflict of interest 0 500 1000 1500 2000 Cancer

¡  Cedars-Sinai§  Moise

Danielpour,M.D.§  JoshuaBreunig,

Ph.D.§  RachelleLevy§  C.Danielle

Antonuk§  JessicaMolina-

Arevena§  GibumKim§  AslamAkhtar§  MarinaDutra-

Clarke§  HannahPark

§  SergueiBannykh,

M.D.§  CliveSvendsen,

Ph.D.§  JavierRodriguez§  DavidGate§  PaskoRakicM.D.,

Ph.D.§  Svendsenlab§  ShawnWagner,Ph.D.§  Townlab

¡  Plasmids§  JoeLoturcoPh.D.§  NenadSestanPh.D.

¡  Addgene

¡  Funding

§  SOCCICancerCenterForumAward

§  VeraandPaulGuerinFamilyFoundation

§  SmidtFamilyFoundation

§  RMIandBiomedicalSciences